
  
    
      
        
        Distal_NNP embolization_NN of_IN particulate_NN matter_NN ,_, including_VBG
        plaque_NN debris_NN and_CC thrombus_JJ ,_, complicate_VB percutaneous_JJ
        coronary_JJ and_CC peripheral_JJ interventions_NNS more_RBR often_RB than_IN had_VBD
        been_VBN recognized_VBN until_IN recently_RB ._. This_DT often_RB results_VBZ in_IN
        diminished_VBN blood_NN flow_NN to_TO the_DT distal_NN vascular_NN bed_NN and_CC is_VBZ
        associated_VBN with_IN periprocedural_NN end-organ_JJ ischemia_NN and_CC
        infarction_NN ,_, as_IN demonstrated_VBN by_IN perfusion_NN defects_NNS and_CC serum_NN
        cardiac_JJ enzyme_NN elevation_NN [_NN 1_CD ,_, 2_CD ]_NN ._. Periprocedural_NNP myocardial_NN
        infarction_NN (_( MI_NNP )_) is_VBZ associated_VBN with_IN a_DT worse_JJR prognosis_NN ,_,
        particularly_RB when_WRB it_PRP is_VBZ large_JJ ,_, which_WDT is_VBZ most_RBS clearly_RB
        demonstrated_VBN in_IN saphenous_JJ vein_NN bypass_NN graft_NN interventions_NNS ._.
        This_DT was_VBD demonstrated_VBN by_IN Hong_NNP 
        et_CC al_NN ._. who_WP studied_VBD 1056_CD consecutive_JJ
        patients_NNS with_IN angiographically_RB successful_JJ percutaneous_JJ
        coronary_JJ intervention_NN of_IN 1693_CD SVG_NNP lesions_NNS [_NN 3_CD ]_NN ._. One-year_NNP
        mortality_NN was_VBD significantly_RB increased_VBN in_IN patients_NNS with_IN
        periprocedural_NN creatine_NN kinase-_NN MB_NNP elevation_NN ,_, even_RB among_IN
        patients_NNS without_IN any_DT apparent_JJ procedure_NN or_CC in-hospital_JJ
        complication_NN ._.
        Distal_NNP embolization_NN of_IN large_JJ particles_NNS at_IN the_DT time_NN of_IN
        balloon_NN inflation_NN or_CC stent_NN deployment_NN may_MD obstruct_VBP large_JJ ,_,
        epicardial_NN vessels_NNS ,_, but_CC the_DT scope_NN of_IN the_DT problem_NN includes_VBZ
        microvascular_NN obstruction_NN due_JJ to_TO very_RB small_JJ particles_NNS ,_, as_RB
        little_JJ as_IN 15_CD -_: 100_CD microns_NNS ,_, that_WDT may_MD result_VB in_IN microinfarcts_NNS
        and_CC left_VBD ventricular_NN dysfunction_NN [_NN 4_CD ]_NN ._. It_PRP is_VBZ likely_JJ that_IN
        mechanical_JJ microvascular_NN obstruction_NN is_VBZ commonly_RB aggravated_VBN
        by_IN secondary_JJ spasm_NN and_CC edema_NN due_JJ to_TO release_NN of_IN humoral_NN
        agonists_NNS by_IN platelets_NNS ,_, and_CC endothelial_NN injury_NN and_CC
        dysfunction_NN ._. Limited_NNP therapeutic_JJ success_NN has_VBZ been_VBN reported_VBN
        from_IN observational_NN studies_NNS involving_VBG the_DT use_NN of_IN calcium_NN
        channel_NN blockers_NNS ,_, adenosine_NN ,_, and_CC sodium_NN nitroprusside_NN [_NN 5_CD ]_NN ._.
        However_RB ,_, the_DT success_NN of_IN these_DT medical_JJ interventions_NNS is_VBZ most_RBS
        commonly_RB defined_VBN by_IN angiographic_JJ resolution_NN of_IN the_DT
        "_'' no-reflow_JJ "_'' phenomenon_NN (_( an_DT acute_JJ reduction_NN in_IN coronary_JJ flow_NN
        less_JJR than_IN Thrombolysis_NNP in_IN Myocardial_NNP Infarction_NNP [_NN TIMI_NNP ]_NN 2_CD in_IN
        the_DT absence_NN of_IN dissection_NN ,_, thrombus_JJ ,_, spasm_NN ,_, or_CC high-grade_JJ
        residual_JJ stenosis_NNS at_IN the_DT original_JJ target_NN lesion_NN )_) ._. A_DT
        beneficial_JJ effect_NN on_IN hard_JJ clinical_JJ endpoints_NNS has_VBZ been_VBN more_RBR
        difficult_JJ to_TO prove_VB ._.
      
      
        Glycoprotein_NNP IIb_NNP /_NN IIIa_NNP inhibitors_NNS and_CC percutaneous_JJ
        coronary_JJ intervention_NN
        Glycoprotein_NNP (_( GP_NNP )_) IIb_NNP /_NN IIIa_NNP inhibitors_NNS reduce_VBP not_RB only_RB
        procedural_JJ infarctions_NNS ,_, but_CC also_RB major_JJ adverse_JJ clinical_JJ
        events_NNS in_IN patients_NNS undergoing_VBG percutaneous_JJ coronary_JJ
        intervention_NN ._. The_DT benefit_NN is_VBZ thought_VBN to_TO be_VB ,_, in_IN part_NN ,_, due_JJ to_TO
        a_DT reduction_NN in_IN the_DT incidence_NN of_IN ischemic_JJ complications_NNS ,_,
        which_WDT is_VBZ likely_JJ to_TO be_VB secondary_JJ to_TO prevention_NN of_IN platelet_NN
        aggregation_NN ,_, thrombus_JJ formation_NN ,_, and_CC distal_NN embolization_NN ,_,
        in_IN native_JJ coronary_JJ arteries_NNS [_NN 6_CD ]_NN ._. These_DT benefits_NNS ,_, however_RB ,_,
        have_VBP been_VBN apparent_JJ in_IN subset_NN analyses_NNS of_IN clinical_JJ trials_NNS ,_,
        or_CC in_IN observational_NN studies_NNS designed_VBN to_TO specifically_RB assess_VB
        their_PRP$ efficacy_NN in_IN saphenous_JJ vein_NN graft_NN interventions_NNS ._.
        Despite_IN suggestion_NN of_IN benefit_NN as_IN measured_VBN by_IN surrogate_JJ
        angiographic_JJ endpoints_NNS ,_, there_EX is_VBZ no_DT evidence_NN of_IN a_DT
        consistent_JJ and_CC sustained_VBN meaningful_JJ clinical_JJ benefit_NN [_NN 7_CD ,_,
        8_CD ]_NN ._. The_DT likely_JJ explanation_NN for_IN this_DT apparent_JJ lack_NN of_IN
        benefit_NN in_IN vein_NN graft_NN interventions_NNS ,_, when_WRB GP_NNP IIb_NNP /_NN IIIa_NNP
        inhibitors_NNS clearly_RB reduce_VBP procedural_JJ infarctions_NNS by_IN
        approximately_RB 50_CD %_NN ,_, is_VBZ the_DT difference_NN in_IN the_DT composition_NN of_IN
        the_DT embolic_JJ material_NN ._. Distal_NNP embolization_NN during_IN saphenous_JJ
        vein_NN graft_NN intervention_NN is_VBZ predominantly_RB due_JJ to_TO soft_JJ
        acellular_NN atheromatous_JJ material_NN typically_RB found_VBD under_IN the_DT
        fibrous_JJ cap_NN (_( cholesterol_NN clefts_NNS ,_, lipid-rich_JJ macrophages_NNS ,_,
        and_CC fibrin_NN material_NN )_) that_WDT occurs_VBZ in_IN >_NN 10_CD %_NN of_IN
        interventions_NNS on_IN vein_NN grafts_NNS that_WDT are_VBP more_JJR than_IN three_CD years_NNS
        old_JJ [_NN 9_CD ]_NN ._. Independent_JJ predictors_NNS of_IN distal_NN embolization_NN
        include_VBP diffuse_NN degeneration_NN and_CC large_JJ plaque_NN volume_NN rather_RB
        than_IN thrombus_JJ ,_, and_CC angioscopy_NN studies_NNS have_VBP found_VBN that_DT vein_NN
        graft_NN friability_NN ,_, rather_RB than_IN thrombus_JJ ,_, was_VBD a_DT stronger_JJR
        predictor_NN of_IN distal_NN embolization_NN and_CC '_POS no-reflow_JJ '_POS [_NN 9_CD ,_, 10_CD ]_NN ._.
        The_DT relative_JJ contribution_NN of_IN platelet_NN aggregates_NNS or_CC
        atheromatous_JJ material_NN to_TO distal_NN embolization_NN and_CC vessel_NN
        occlusion_NN in_IN native_JJ coronary_JJ arteries_NNS is_VBZ unclear_JJ ._. Despite_IN
        these_DT aforementioned_JJ beneficial_JJ effects_NNS of_IN aggressive_JJ
        platelet_NN inhibition_NN during_IN percutaneous_JJ coronary_JJ
        intervention_NN ,_, however_RB ,_, further_JJ reductions_NNS in_IN distal_NN
        embolization_NN remains_VBZ an_DT important_JJ goal_NN ,_, particularly_RB in_IN the_DT
        acute_JJ coronary_JJ syndromes_NNS ._.
      
      
        Percutaneous_NNP carotid_NN interventions_NNS
        Percutaneous_NNP carotid_NN interventions_NNS are_VBP frequently_RB
        complicated_VBN by_IN embolization_NN [_NN 11_CD ]_NN ._. Jordan_NNP 
        et_CC al_NN ._. and_CC others_NNS have_VBP demonstrated_VBN
        that_IN there_EX is_VBZ Doppler_NNP evidence_NN of_IN microembolization_NN during_IN
        almost_RB all_DT carotid_NN stenting_VBG procedures_NNS [_NN 12_CD ]_NN ._. The_DT precise_JJ
        clinical_JJ significance_NN of_IN this_DT phenomenon_NN remains_VBZ unclear_JJ ,_,
        since_IN the_DT brain_NN appears_VBZ to_TO have_VB a_DT surprising_JJ tolerance_NN for_IN
        microembolization_NN in_IN the_DT acute_JJ setting_NN ._. No_DT one_NN has_VBZ yet_RB
        linked_VBN these_DT emboli_NN to_TO adverse_JJ clinical_JJ events_NNS ._. However_RB ,_,
        even_RB small_JJ plaque_NN fragments_NNS less_JJR than_IN 200_CD microns_NNS may_MD cause_VB
        neuronal_NN ischemia_NN at_IN later_RB time_NN points_NNS ,_, and_CC periprocedural_NN
        microemboli_NN may_MD be_VB responsible_JJ for_IN both_DT stroke_NN and_CC more_RBR
        subtle_JJ neurologic_JJ dysfunction_NN in_IN late_JJ follow-up_JJ [_NN 13_CD ,_, 14_CD ]_NN ._.
        Carotid_NNP angioplasty_NN and_CC stenting_VBG is_VBZ associated_VBN with_IN a_DT
        perioperative_JJ stroke_NN rate_NN exceeding_VBG 3_CD %_NN in_IN most_JJS series_NN ,_,
        largely_RB due_JJ to_TO emboli_NN ._. Additionally_RB ,_, this_DT embolic_JJ
        complication_NN continues_VBZ to_TO limit_VB the_DT applicability_NN of_IN
        percutaneous_JJ revascularization_NN in_IN patients_NNS who_WP are_VBP suitable_JJ
        for_IN surgical_JJ carotid_NN endarterectomy_NN [_NN 15_CD ]_NN ._.
      
      
        Balloon_NN occlusion_NN devices_NNS :_: PercuSurge_NNP
        GuardWire_NNP
        A_DT number_NN of_IN distal_NN protection_NN devices_NNS that_WDT aim_NN to_TO reduce_VB
        or_CC eliminate_VB distal_NN embolization_NN during_IN percutaneous_JJ
        coronary_JJ and_CC carotid_NN interventions_NNS are_VBP under_IN development_NN
        (_( Table_NNP 1_LS )_) ._.
        Only_RB one_CD such_JJ device_NN has_VBZ already_RB been_VBN approved_VBN for_IN use_NN
        by_IN the_DT United_NNP States_NNPS Food_NNP and_CC Drug_NNP Administration_NNP (_( FDA_NNP )_) ._.
        The_DT PercuSurge_NNP GuardWire_NNP (_( Medtronic_NNP ,_, Santa_NNP Rosa_NNP ,_, CA_NNP ,_, USA_NNP )_)
        is_VBZ an_DT occlusion_NN thrombectomy_NN device_NN that_WDT consists_VBZ of_IN a_DT wire_NN
        containing_VBG a_DT central_JJ lumen_NN that_IN communicates_NNS with_IN a_DT
        low-pressure_JJ distal_NN occlusion_NN balloon_NN incorporated_VBN into_IN the_DT
        tip_NN (_( Fig_NNP ._. 1_LS )_) ._. The_DT wire_NN serves_VBZ as_IN both_DT the_DT angioplasty_NN
        guidewire_NN and_CC provides_VBZ protection_NN from_IN distal_NN embolization_NN ._.
        An_DT inflation_NN device_NN allows_VBZ controlled_VBN expansion_NN and_CC sizing_VBG
        of_IN the_DT occlusion_NN balloon_NN in_IN the_DT treated_VBN vessel_NN ._. An_DT
        aspiration_NN catheter_NN is_VBZ used_VBN to_TO remove_VB the_DT debris_NN from_IN the_DT
        treated_VBN vessel_NN before_IN the_DT balloon_NN is_VBZ deflated_VBN and_CC antegrade_NN
        flow_NN in_IN the_DT treated_VBN vessel_NN is_VBZ restored_VBN ._.
        The_DT Saphenous_NNP Vein_NNP Graft_NNP Angioplasty_NNP Free_NNP of_IN Emboli_NNP
        (_( SAFE_NNP )_) study_NN evaluated_VBD the_DT safety_NN and_CC feasibility_NN of_IN this_DT
        device_NN [_NN 16_CD ]_NN ._. Initial_JJ encouraging_VBG results_NNS in_IN the_DT European_JJ
        and_CC Canadian_JJ registries_NNS were_VBD confirmed_VBN in_IN the_DT Saphenous_NNP
        Vein_NNP Graft_NNP Angioplasty_NNP Free_NNP of_IN Emboli_NNP ,_, Randomized_NNP (_( SAFER_NNP )_)
        trial_NN conducted_VBN in_IN the_DT United_NNP States_NNPS (_( US_NNP )_) [_NN 17_CD ]_NN ._. The_DT SAFER_NNP
        trial_NN was_VBD conducted_VBN at_IN 47_CD sites_NNS and_CC enrolled_VBD 659_CD patients_NNS
        undergoing_VBG saphenous_JJ vein_NN graft_NN percutaneous_JJ coronary_JJ
        intervention_NN ._. Inclusion_NNP criteria_NNS were_VBD stenoses_NNS of_IN 50_CD -_: 99_CD %_NN in_IN
        saphenous_JJ vein_NN grafts_NNS 3_CD -_: 6_CD mm_NN in_IN diameter_NN ,_, more_JJR than_IN 5_CD mm_NN
        from_IN the_DT ostium_NN and_CC 20_CD mm_NN from_IN the_DT distal_NN anastamosis_NNS ,_, and_CC
        at_IN least_JJS TIMI_NNP 1_CD flow_NN at_IN baseline_NN ._. Exclusion_NNP criteria_NNS
        included_VBD acute_JJ MI_NNP ,_, ejection_NN fraction_NN <_NN 25_CD %_NN ,_, creatinine_NN
        >_NN 2_CD ._. 5_LS mg_NN /_NN dL_NN (_( unless_IN on_IN hemodialysis_NNS )_) ,_, and_CC planned_VBD use_NN of_IN
        an_DT atherectomy_NN device_NN ._. The_DT primary_JJ endpoint_NN was_VBD the_DT
        occurrence_NN of_IN major_JJ adverse_JJ clinical_JJ events_NNS at_IN 30_CD days_NNS ,_,
        including_VBG death_NN ,_, MI_NNP ,_, emergency_NN bypass_NN surgery_NN ,_, and_CC repeat_NN
        target_NN vessel_NN revascularization_NN ._.
        Pre-specified_NNP secondary_JJ endpoints_NNS were_VBD the_DT frequency_NN
        with_IN which_WDT TIMI_NNP 3_CD flow_NN was_VBD achieved_VBN ,_, and_CC clinically_RB
        apparent_JJ no-flow_JJ occurred_VBD ._. The_DT GuardWire_NNP was_VBD superior_JJ to_TO
        '_POS standard_JJ care_NN '_'' (_( Figs_NNP 2_CD and_CC 3_LS )_) ._. There_EX was_VBD a_DT 50_CD %_NN relative_JJ
        reduction_NN in_IN cumulative_JJ 30_CD -_: day_NN major_JJ adverse_JJ cardiac_JJ events_NNS
        (_( 17_CD ._. 8_CD %_NN to_TO 9_CD ._. 0_CD %_NN ,_, 
        P_NN =_SYM 0_CD ._. 001_CD )_) ,_, a_DT 68_CD %_NN relative_JJ reduction_NN
        in_IN mortality_NN (_( 2_CD ._. 8_CD %_NN to_TO 0_CD ._. 9_CD %_NN ,_, 
        P_NN =_SYM 0_CD ._. 086_CD )_) ,_, and_CC a_DT 49_CD %_NN relative_JJ
        reduction_NN in_IN MI_NNP (_( 17_CD ._. 3_LS %_NN to_TO 8_CD ._. 8_CD %_NN ,_, 
        P_NN =_SYM 0_CD ._. 003_CD )_) ._. The_DT trial_NN was_VBD stopped_VBN
        early_RB by_IN the_DT data_NNS safety_NN monitoring_VBG board_NN ,_, and_CC the_DT
        manufacturer_NN promptly_RB secured_VBD FDA_NNP approval_NN ._.
        Interestingly_RB ,_, although_IN GP_NNP IIb_NNP /_NN IIIa_NNP inhibitors_NNS were_VBD used_VBN
        in_IN >_NN 60_CD %_NN of_IN all_DT patients_NNS ,_, predominantly_RB before_IN
        intervention_NN ,_, major_JJ adverse_JJ clinical_JJ events_NNS were_VBD more_RBR
        common_JJ amongst_IN those_DT receiving_VBG the_DT drug_NN ._. Since_IN this_DT was_VBD a_DT
        non_NN randomized_JJ ,_, retrospective_NN analysis_NN ,_, no_DT conclusions_NNS
        about_IN a_DT potentially_RB beneficial_JJ (_( or_CC deleterious_JJ )_) affect_VB can_MD
        be_VB made_VBN ._. However_RB ,_, it_PRP is_VBZ apparent_JJ that_IN the_DT reduction_NN in_IN
        major_JJ adverse_JJ clinical_JJ events_NNS in_IN the_DT GuardWire_NNP arm_NN was_VBD
        independent_JJ of_IN the_DT use_NN of_IN GP_NNP IIb_NNP /_NN IIIa_NNP inhibitors_NNS ._.
        Similarly_RB ,_, the_DT feasibility_NN and_CC safety_NN of_IN carotid_NN
        angioplasty_NN and_CC stenting_VBG using_VBG the_DT PercuSurge_NNP GuardWire_NNP
        system_NN has_VBZ been_VBN determined_VBN [_NN 10_CD ]_NN ._. Technical_JJ success_NN was_VBD
        reported_VBN in_IN a_DT series_NN of_IN 48_CD high-risk_JJ patients_NNS (_( 39_CD men_NNS ,_, mean_VB
        age_NN 69_CD ._. 1_LS ±_NN 8_CD years_NNS )_) with_IN 53_CD internal_JJ carotid_NN artery_NN
        stenoses_NNS ._. Mean_VB cerebral_JJ flow_NN occlusion_NN time_NN was_VBD 346_CD ±_NN 153_CD
        seconds_NNS during_IN predilation_NN and_CC 303_CD ±_NN 143_CD seconds_NNS during_IN
        stent_NN placement_NN ._. One_CD immediate_JJ neurological_JJ complication_NN
        (_( transient_JJ amaurosis_NNS fugax_NN )_) was_VBD documented_VBN in_IN a_DT patient_NN who_WP
        had_VBD a_DT surgical_JJ anastamosis_NNS between_IN the_DT external_JJ and_CC
        internal_JJ carotid_NN arteries_NNS ._.
      
      
        Filter_NNP Devices_NNPS
        
          AngioGuard_NNP ™_NN
          A_DT second_JJ '_POS class_NN '_'' of_IN distal_NN protection_NN devices_NNS under_IN
          development_NN and_CC currently_RB undergoing_VBG clinical_JJ
          investigation_NN are_VBP the_DT filter_NN devices_NNS ._. AngioGuard_NNP (_( Cordis_NNP
          Corp_NNP ._. ,_, Minneapolis_NNP ,_, MN_NNP ,_, USA_NNP )_) is_VBZ an_DT example_NN of_IN such_JJ a_DT
          device_NN that_WDT has_VBZ recently_RB received_VBN approval_NN for_IN marketing_NN
          in_IN Europe_NNP ._. AngioGuard_NNP 's_POS technology_NN incorporates_VBZ an_DT
          angioplasty_NN guidewire_NN with_IN a_DT filter_NN that_WDT expands_VBZ to_TO 6_CD mm_NN
          and_CC is_VBZ placed_VBN distal_NN to_TO the_DT target_NN lesion_NN to_TO capture_VB and_CC
          retrieve_VB embolic_JJ debris_NN (_( Fig_NNP ._. 4_LS )_) ._. At_IN the_DT end_NN of_IN the_DT
          procedure_NN ,_, the_DT filter_NN is_VBZ collapsed_VBN ,_, trapping_VBG the_DT
          particulate_NN matter_NN and_CC facilitating_VBG removal_NN from_IN the_DT
          artery_NN ._.
          The_DT AngioGuard_NNP filter_NN has_VBZ multiple_JJ ,_, 100_CD micron_NN ,_,
          laser-drilled_JJ holes_NNS that_WDT allow_VBP perfusion_NN during_IN device_NN
          deployment_NN ._. It_PRP has_VBZ been_VBN proposed_VBN that_IN this_DT is_VBZ a_DT major_JJ
          advantage_NN of_IN filter_NN devices_NNS ._. In_IN contrast_NN ,_, the_DT balloon_NN
          occlusion_NN devices_NNS result_VBP in_IN complete_JJ cessation_NN of_IN
          antegrade_NN flow_NN for_IN as_RB long_RB as_IN it_PRP takes_VBZ to_TO treat_VB the_DT
          vessel_NN and_CC aspirate_NN the_DT debris_NN (_( typically_RB 2_CD -_: 3_CD minutes_NNS in_IN
          the_DT hands_NNS of_IN experienced_VBN operators_NNS )_) [_NN 9_CD ,_, 15_CD ]_NN ._. This_DT is_VBZ a_DT
          critical_JJ clinical_JJ consideration_NN in_IN patients_NNS with_IN reduced_VBN
          left_VBD ventricular_NN function_NN or_CC in_IN patients_NNS in_IN whom_WP the_DT
          treated_VBN artery_NN supplies_VBZ a_DT large_JJ amount_NN of_IN myocardium_NN ._.
          Conversely_RB ,_, it_PRP has_VBZ been_VBN proposed_VBN that_IN incomplete_JJ vessel_NN
          occlusion_NN with_IN the_DT filter_NN devices_NNS allows_VBZ passage_NN of_IN
          debris_NN through_IN the_DT holes_NNS of_IN the_DT filter_NN devices_NNS ._. Indeed_RB ,_,
          analysis_NN of_IN debris_NN retrieved_VBN by_IN the_DT balloon_NN occlusion_NN
          thrombectomy_NN device_NN in_IN the_DT SAFE_NNP trial_NN device_NN found_VBD that_IN
          80_CD %_NN of_IN the_DT particulate_NN matter_NN was_VBD less_JJR than_IN 100_CD microns_NNS
          in_IN diameter_NN ._. The_DT clinical_JJ significance_NN of_IN such_JJ small_JJ
          embolic_JJ particles_NNS is_VBZ unclear_JJ ,_, and_CC difficult_JJ to_TO resolve_VB
          since_IN the_DT completeness_NN of_IN debris_NN entrapment_NN by_IN any_DT distal_NN
          protection_NN device_NN is_VBZ impossible_JJ to_TO determine_VB in_IN clinical_JJ
          practice_NN ._.
          The_DT initial_JJ experience_NN with_IN the_DT AngioGuard_NNP filter_NN
          device_NN is_VBZ promising_JJ ._. A_DT phase_NN I_PRP trial_NN in_IN 33_CD consecutive_JJ
          lesions_NNS (_( in_IN 31_CD patients_NNS )_) of_IN the_DT internal_JJ carotid_NN artery_NN
          documented_VBN successful_JJ deployment_NN of_IN the_DT filter_NN in_IN 82_CD %_NN of_IN
          the_DT lesions_NNS ._. Debris_NNP that_WDT might_MD have_VB been_VBN expected_VBN to_TO
          result_VB in_IN distal_NN vessel_NN occlusion_NN was_VBD collected_VBN in_IN 80_CD %_NN of_IN
          cases_NNS ._. This_DT technology_NN is_VBZ currently_RB under_IN investigation_NN
          in_IN the_DT US_NNP for_IN both_DT carotid_NN and_CC coronary_JJ percutaneous_JJ
          interventions_NNS in_IN appropriately_RB sized_VBD trials_NNS ._.
          The_DT Study_NNP of_IN Angioplasty_NNP with_IN Protection_NNP in_IN Patients_NNPS
          at_IN High_NNP Risk_NNP for_IN Endarterectomy_NNP (_( SAPPHIRE_NNP )_) is_VBZ examining_VBG
          the_DT benefits_NNS of_IN the_DT AngioGuard_NNP device_NN among_IN 720_CD patients_NNS
          undergoing_VBG carotid_NN artery_NN stenting_VBG in_IN a_DT randomized_JJ trial_NN
          versus_CC '_POS standard_JJ care_NN '_'' (_( no_DT distal_NN protection_NN device_NN )_) [_NN
          18_CD ]_NN ._. The_DT Saphenous_NNP Vein_NNP Graft_NNP Intervention_NN using_VBG
          AngioGuard_NNP for_IN reduction_NN of_IN Distal_NNP Embolization_NNP (_( GUARD_NNP )_)
          trial_NN is_VBZ also_RB ongoing_JJ and_CC will_MD determine_VB the_DT efficacy_NN of_IN
          this_DT device_NN in_IN a_DT study_NN population_NN analogous_JJ to_TO the_DT SAFER_NNP
          trial_NN ._. The_DT appropriateness_NN of_IN continuing_VBG such_JJ trials_NNS with_IN
          a_DT control_NN arm_NN without_IN distal_NN protection_NN has_VBZ been_VBN a_DT source_NN
          of_IN controversy_NN ._. The_DT use_NN of_IN the_DT distal_NN protection_NN device_NN
          reduces_VBZ adverse_JJ events_NNS by_IN 50_CD %_NN (_( the_DT PercuSurge_NNP device_NN )_) and_CC
          is_VBZ approved_VBN for_IN use_NN and_CC currently_RB available_JJ ._. As_IN a_DT result_NN ,_,
          the_DT control_NN arms_NNS of_IN these_DT trials_NNS are_VBP now_RB being_VBG
          reconsidered_VBN ._.
        
        
          FilterWire_NNP EX_NNP ™_NN
          The_DT FilterWire_NNP EX_NNP (_( Boston_NNP Scientific_NNP ,_, Natick_NNP ,_, MA_NNP ,_, USA_NNP )_)
          is_VBZ another_DT filter_NN device_NN currently_RB under_IN clinical_JJ
          investigation_NN (_( Fig_NNP ._. 5_LS )_) ._. Similar_JJ to_TO the_DT AngioGuard_NNP ,_, it_PRP is_VBZ
          a_DT low-profile_JJ (_( <_NN 3_CD ._. 5_LS French_JJ )_) filter_NN mounted_VBD on_IN a_DT 0_CD ._. 014_CD
          inch_NN angioplasty_NN wire_NN with_IN pore_NN holes_NNS of_IN 80_CD microns_NNS that_WDT
          permit_VBP antegrade_NN blood_NN flow_NN while_IN providing_VBG distal_NN
          protection_NN ._. The_DT filter_NN design_NN is_VBZ characterized_VBN by_IN an_DT
          off-center_JJ position_NN and_CC '_POS fish-mouth_JJ '_POS opening_NN ,_, and_CC can_MD be_VB
          retracted_VBD into_IN any_DT standard_JJ angioplasty_NN balloon_NN ._. A_DT
          radiopaque_NN nitinol_NN framework_NN provides_VBZ filter_NN support_NN and_CC
          facilitates_NNS fluoroscopic_JJ visualization_NN ._. Initial_JJ corporate_JJ
          reports_NNS of_IN feasibility_NN ,_, safety_NN ,_, and_CC clinical_JJ efficacy_NN are_VBP
          promising_JJ ._. A_DT complication_NN rate_NN of_IN 7_CD %_NN was_VBD reported_VBN during_IN
          61_CD saphenous_JJ vein_NN graft_NN interventions_NNS (_( 4_CD non-_NN Q_NNP wave_NN MIs_NNP )_) ._.
          This_DT compares_VBZ favorably_RB with_IN historical_JJ control_NN rates_NNS of_IN
          >_NN 10_CD %_NN ._. Equally_RB impressive_JJ ,_, unpublished_JJ results_NNS in_IN small_JJ
          numbers_NNS of_IN patients_NNS undergoing_VBG carotid_NN ,_, native_JJ coronary_JJ
          artery_NN ,_, and_CC renal_JJ percutaneous_JJ intervention_NN ,_, will_MD
          hopefully_RB result_VB in_IN randomized_JJ ,_, controlled_VBD clinical_JJ
          trials_NNS to_TO clarify_VB these_DT preliminary_JJ results_NNS ._.
        
        
          MedNova_NNP Neuroshield_NNP ™_NN
          The_DT MedNova_NNP NeuroShield_NNP (_( MedNova_NNP Inc_NNP ._. ,_, Galway_NNP ,_,
          Ireland_NNP )_) is_VBZ a_DT filter_NN that_WDT is_VBZ mounted_VBN on_IN the_DT distal_NN tip_NN of_IN
          a_DT 0_CD ._. 014_CD inch_NN guidewire_NN ,_, and_CC its_PRP$ use_NN requires_VBZ both_DT a_DT
          delivery_NN catheter_NN and_CC a_DT retrieval_NN catheter_NN ._. The_DT filter_NN
          contains_VBZ a_DT pre-shaped_JJ nitinol_NN expansion_NN system_NN that_WDT
          facilitates_NNS fluoroscopic_JJ visualization_NN ,_, accurate_JJ
          deployment_NN ,_, and_CC wall_NN apposition_NN ._. The_DT filter_NN guidewire_NN is_VBZ
          placed_VBN within_IN the_DT delivery_NN catheter_NN and_CC is_VBZ passed_VBN through_IN
          the_DT target_NN stenosis_NNS ,_, the_DT delivery_NN catheter_NN is_VBZ withdrawn_VBN ,_,
          the_DT filter_NN is_VBZ deployed_VBN ,_, and_CC after_IN completion_NN of_IN the_DT
          vascular_NN intervention_NN (_( angioplasty_NN ,_, stenting_VBG ,_, etc_FW ._. )_) the_DT
          retrieval_NN catheter_NN is_VBZ used_VBN to_TO envelop_NN the_DT filter_NN ._. Then_RB ,_,
          the_DT entire_JJ device_NN and_CC its_PRP$ embolic_JJ contents_NNS are_VBP
          withdrawn_VBN ._.
        
      
      
        Catheter_NNP Occlusion_NNP Devices_NNPS
        The_DT Parodi_NNP Anti-_NNP Emboli_NNP System_NNP (_( PAES_NNP ;_: ArteriA_NNP Medical_NNP
        Science_NNP ,_, Inc_NNP ._. ,_, San_NNP Francisco_NNP ,_, CA_NNP ,_, USA_NNP )_) is_VBZ a_DT guiding_VBG
        catheter_NN with_IN an_DT occlusion_NN balloon_NN attached_VBN at_IN its_PRP$ distal_NN
        end_NN (_( Fig_NNP ._. 6_CD )_) ._. The_DT PAES_NNP establishes_VBZ protection_NN by_IN reversing_VBG
        blood_NN flow_NN in_IN the_DT target_NN vessel_NN [_NN 19_CD ,_, 20_CD ]_NN ._. In_IN the_DT carotid_NN
        arteries_NNS ,_, the_DT system_NN works_VBZ by_IN occluding_VBG the_DT common_JJ carotid_NN ,_,
        which_WDT creates_VBZ a_DT negative_JJ pressure_NN gradient_NN distal_NN to_TO the_DT
        balloon_NN occlusion_NN and_CC establishes_VBZ retrograde_NN flow_NN in_IN the_DT
        internal_JJ carotid_NN artery_NN ._. The_DT external_JJ carotid_NN is_VBZ also_RB
        occluded_JJ to_TO avoid_VB flow_NN traveling_VBG from_IN the_DT external_JJ one_CD back_RB
        up_RP the_DT internal_JJ one_CD ._. This_DT system_NN establishes_VBZ protection_NN
        without_IN the_DT risk_NN of_IN disruption_NN of_IN the_DT target_NN lesion_NN ,_,
        thereby_RB reducing_VBG the_DT risk_NN of_IN embolic_JJ stroke_NN during_IN device_NN
        deployment_NN prior_RB to_TO percutaneous_JJ intervention_NN ._.
        The_DT company_NN reports_NNS performance_NN of_IN 200_CD cases_NNS worldwide_NN
        (_( in_IN Italy_NNP ,_, Argentina_NNP ,_, New_NNP Zealand_NNP ,_, Australia_NNP ,_, Germany_NNP ,_,
        Belgium_NNP ,_, France_NNP ,_, and_CC Sweden_NNP )_) ,_, with_IN 100_CD %_NN successful_JJ
        deployment_NN and_CC no_DT ipsilateral_NN embolic_JJ events_NNS ._. Two_CD patients_NNS
        suffered_VBD an_DT intracranial_NN hemorrhage_NN ,_, one_CD patient_NN died_VBD
        following_VBG a_DT periprocedural_NN MI_NNP ,_, one_CD patient_NN had_VBD a_DT
        contralateral_NN embolic_JJ event_NN during_IN a_DT coronary_JJ artery_NN bypass_NN
        graft_NN procedure_NN performed_VBN at_IN the_DT same_JJ time_NN ,_, and_CC one_CD patient_NN
        had_VBD a_DT minor_JJ contralateral_NN ischemic_JJ stroke_NN ._. A_DT small_JJ
        Investigational_NNP Device_NN Exemption_NNP (_( IDE_NNP )_) clinical_JJ study_NN in_IN
        the_DT US_NNP is_VBZ planned_VBN ._.
      
      
        Conclusion_NNP
        There_EX remains_VBZ great_JJ controversy_NN about_IN the_DT clinical_JJ
        significance_NN of_IN the_DT procedural_JJ infarctions_NNS that_WDT occur_VBP in_IN
        approximately_RB 10_CD %_NN of_IN percutaneous_JJ interventions_NNS in_IN the_DT
        native_JJ coronary_JJ arteries_NNS ,_, and_CC particularly_RB the_DT small_JJ
        subclinical_JJ infarctions_NNS that_WDT occur_VBP during_IN otherwise_RB
        successful_JJ procedures_NNS ._. There_EX is_VBZ nothing_NN controversial_JJ or_CC
        subtle_JJ ,_, however_RB ,_, about_IN a_DT great_JJ many_JJ of_IN the_DT embolic_JJ
        infarctions_NNS that_WDT occur_VBP during_IN vein_NN graft_NN or_CC carotid_NN
        interventions_NNS ._. Neither_DT the_DT approved_VBN device_NN nor_CC the_DT devices_NNS
        under_IN investigation_NN are_VBP ,_, at_IN present_JJ ,_, perfect_JJ ._. Doubtless_NNP all_DT
        will_MD undergo_VB improvements_NNS in_IN the_DT future_NN ,_, and_CC offer_NN hope_VBP for_IN
        further_JJ increasing_VBG the_DT safety_NN of_IN high-risk_JJ percutaneous_JJ
        interventions_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        GUARD_NNP =_SYM Saphenous_NNP Vein_NNP Graft_NNP Intervention_NN using_VBG
        AngioGuard_NNP for_IN Reduction_NNP of_IN Distal_NNP Embolization_NNP trial_NN ;_: SAFE_NNP
        =_SYM Saphenous_NNP Vein_NNP Graft_NNP Angioplasty_NNP Free_NNP of_IN Emboli_NNP study_NN ;_:
        SAFER_NNP =_SYM Saphenous_NNP Vein_NNP Graft_NNP Angioplasty_NNP Free_NNP of_IN Emboli_NNP ,_,
        Randomized_NNP trial_NN ;_: SAPPHIRE_NNP =_SYM The_DT Study_NNP of_IN Angioplasty_NNP with_IN
        Protection_NNP in_IN Patients_NNPS at_IN High_NNP Risk_NNP for_IN Endarterectomy_NNP ;_:
        TIMI_NNP =_SYM Thrombolysis_NNP in_IN Myocardial_NNP Infarction_NNP ._.
        FDA_NNP =_SYM United_NNP States_NNPS Food_NNP and_CC Drug_NNP Administration_NNP ;_: GP_NNP =_SYM
        glycoprotein_NN ;_: MI_NNP =_SYM myocardial_NN infarction_NN ;_: PAES_NNP =_SYM Parodi_NNP
        Anti-_NNP Emboli_NNP System_NNP ;_: US_NNP =_SYM United_NNP States_NNPS ._.
      
    
  
